Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label, Dose-escalation and Dose-expansion Study of the Safety and Pharmacokinetics of HB0025 in Patients With Advanced Solid Tumors

NCT04678908 is registered in ClinicalTrials.gov with Huabo Biopharm Co., Ltd. as lead sponsor.

NCT NCT04678908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04678908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label, Dose-escalation and Dose-expansion Study of the Safety and Pharmacokinetics of HB0025 in Patients With Advanced Solid Tumors
Lead sponsor
Huabo Biopharm Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
March 10, 2021
Completion date
May 23, 2024
Enrollment
154 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

tumor, subjects